Actively Recruiting
Study of Increasing Doses of Alisertib with Paclitaxel in Patients with Small Cell Lung Cancer
Led by Puma Biotechnology, Inc. · Updated on 2026-11-02
50
Participants Needed
11
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well people with small cell lung cancer SCLC tolerate different doses of alisertib when combined with paclitaxel. This Phase 2 open-label trial focuses on patients who have had prior treatments including platinum-based chemotherapy and immunotherapy. The study aims to understand the side effects participants experience based on standardized criteria during treatment cycles. Participants take alisertib orally twice a day from Day 1 through Day 7 in each 21-day cycle, with doses starting at 30 mg twice daily and increasing by 10 mg in successive groups of about ten participants. Paclitaxel is given intravenously on Days 1 and 8 of each cycle. After each cycle involving alisertib, participants receive a preventive injection called granulocyte-colony stimulating factor G-CSF to support the bodys defenses. Blood samples are collected on Days 1 and 7 of the first two cycles to monitor alisertib levels. Treatment continues until disease progression, unacceptable side effects, death, or withdrawal from the study. After stopping treatment, participants enter a long-term follow-up phase with contact every 8 weeks until death, study end, or withdrawal. Researchers assess side effects, response to treatment, disease control, progression-free survival, and overall survival over up to 24 months, carefully monitoring safety throughout the study.
CONDITIONS
Brief Title
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Research Team
P
Puma Biotechnology, Inc. Clinical Operations Senior Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here